Buprenorphine/Naloxone for Opiate-Dependence Treatment - 1
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate-dependence treatment. The developmental objective for this combination product is an expansion of therapeutic options for the treatment of opiate dependence.
This multicenter pivotal clinical trial was comprised of two phases. The first phase, which was four weeks in length, was double-blind placebo controlled and was primarily used to evaluate the efficacy of buprenorphine/naloxone. The second phase, lasting 48 weeks, was primarily conducted to determine the safety of buprenorphine/naloxone.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
23 Years to 59 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
DSM-IV (Diagnostic and Statistical Manual of the American Psychiatric Association) diagnosis of current opiate dependence.
Individuals seeking opiate-substitution pharmacotherapy for opiate dependence.
Males and non-pregnant, non-nursing females, 18 to 59 years of age (inclusive).
Individuals able to give informed consent and willing to comply with all study procedures (e.g., providing of urine samples under observation, completing questionnaires).
Any acute or chronic medical condition that would make participation in the study medically hazardous (e.g., acute hepatitis, unstable cardiovascular, hepatic, or renal disease, unstable diabetes, symptomatic AIDS; not HIV-seropositivity alone).
Aspartate or alanine aminotransferase (AST, ALT) levels greater than three times the upper limit of normal.
Individuals currently taking systemic anti-retroviral or anti-fungal therapy.
Current dependence (by DSM-IV criteria) on any psychoactive substance other than opiates, caffeine, or nicotine.
Current, primary, Axis I psychiatric diagnosis other than opiate, caffeine, or nicotine dependence.
Females of childbearing potential who do not agree to use a medically acceptable method of birth control. Acceptable methods include
barrier (diaphragm or condom) - a spermicide is not required due to the possibility of local irritation and allergic type reactions, but are recommended for use,
intrauterine progesterone contraceptive system,
medroxyprogesterone acetate contraceptive injection, or
Enrollment in an opiate-substitution (i.e., methadone, levo-alpha-acetylmethadol) treatment program within 45 days of enrolling in the present study.
Individuals having taken (licitly or illicitly) LAAM, methadone, or naltrexone within days of enrolling in the present study.
Individuals having taken buprenorphine, other than as an analgesic, within 365 days of enrolling in the present study.
Participation in an investigational drug or device study within 45 days of enrolling in the present study.
Anyone, who in the opinion of site principal investigator, would not be expected to complete the first phase of the study protocol (e.g., due to pending incarceration or probable relocation from the clinic area).